Parabilis Medicines, Inc is a biopharmaceutical company pioneering the discovery and development of Helicon™ peptide therapeutics; these ultra diverse alpha-helical peptides are capable of efficient cell entry and modulation of both protein-protein and protein-DNA interactions. Through Helicon therapeutics, Parabilis is poised to revolutionize the medical possibilities for patients by precisely drugging intracellular targets long understood to be significant drivers of disease but never before drugged due to the limitations of existing drug modalities to act within the cell. FOG-001, the company’s first-in-class TCF-blocking β-catenin inhibitor, is being evaluated in a Phase 1/2 study for patients with advanced solid tumors, including desmoid tumors and colorectal cancer. Parabilis is fully leveraging the unprecedented potential Helicons present by deploying proprietary, custom-built machine learning and computational methods as part of its discovery and development process. Parabilis Medicines has raised more than $500 million to date from leading life sciences investors. Parabilis is headquartered in Cambridge, Mass. As a senior scientist at Parabilis and a biology lead for a preclinical oncology program, you’ll help drive the biological strategy through candidate selection and IND-enabling studies, integrating mechanistic insight and in vitro/in vivo pharmacology for our one of our novel Helicon TM peptide programs. We’re looking for a highly motivated Senior Scientist with significant experience in cell and molecular biology to report to the Sr. Director, Biology.